急性冠状动脉综合征患者血清对氧磷酶1的活性及其临床意义被引量：3

下载PDF

导出

摘要目的探讨急性冠状动脉综合征(ACS)患者血清对氧磷酶1(PON1)的活性及其与冠状动脉病变支数以及ACS类型的关系。方法选择2012年7月至2014年7月在该院诊断为ACS患者123例与非冠心病患者(对照组)20例。将123例ACS患者分为以下3个亚组:不稳定型心绞痛(UAP)组46例,非ST段抬高型急性心肌梗死(NSTEMI)组36例,ST段抬高型急性心肌梗死(STEMI)组41例。采用分光光度计测定各组人群血清PON1的活性。采用Spearman相关分析研究PON1水平与ACS亚型和冠状动脉造影显示的冠状动脉病变支数的相关性。结果 ACS患者的血清PON1活性显著低于对照组。UAP组的PON1水平高于NSTEMI组与STEMI组(P<0.05),NSTEMI组的PON1水平高于STEMI组(P<0.05),且PON1的水平与ACS的临床亚型呈负相关(r=-0.287,P<0.05)。单支病变组的PON1水平显著高于二支和三支病变组(P<0.05),PON1水平在二支病变组明显高于三支病变组(P<0.05),且PON1与冠状动脉病变支数呈明显的负相关(r=-0.527,P<0.05)。结论ACS患者的血清PON1水平明显降低并与ACS的临床亚型及冠状动脉病变支数密切相关。

作者周齐艳周娟蒋恒波

机构地区湖南省永州职业技术学院附属医院心血管内科

出处《重庆医学》 CAS 北大核心 2015年第36期5119-5121,共3页 Chongqing medicine

基金湖南省科技厅基金资助项目(2014SK3156)

关键词对氧磷酶1 急性冠状动脉综合征冠状动脉病变

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Ding J, Chen Q, Zhuang X, et al. Low paraoxonase 1 arylesterase activity and high yon Willebrand factor levels are associated with severe coronary atherosc|erosis in pa- tients with non-diabetic stable coronary artery disease [J]. Med Sci Monit, 2014,20 : 2421-2429.
2赵莉,姚树桐,王义围,秦树存.高密度脂蛋白蛋白成分修饰对其抗动脉粥样硬化功能的影响[J].中国动脉硬化杂志,2014,22(10):1067-1071. 被引量：10
3Xu RX, Li S, Li XL, et al. High-density lipoprotein sub- fractions in relation with the severity of coronary artery disease:A Gensini score assessment[J]. J Clin Lipidol, 2015,9(1) :26-34.
4Tan Y, Liu TR, Hu SW, et al. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions [J]. PLoS One, 2014, 9 ( 4 ): e94264.
5王非,江渝.对氧磷酶2研究进展[J].重庆医学,2013,42(12):1410-1412. 被引量：4
6Bounafaa A, Berrougui H, Ikhlef S, et al. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients[J]. Clin Biochem, 2014,47 (18) : 318- 325.
7Emami Razavi A, Basati G, Varshosaz J, et al. Associa- tionbetween HDL particles size and myeloperoxidase/ paraoxonase-l(MPO/PON1) ratio in patients with acute coronary syndrome[J]. Acta Med Iran, 2013,51 (6) : 365- 371.
8Karlsson H, Kontush A, James RW. Functionality of HDL: antioxidation and detoxifying effects[J]. Handb Exp Pharma-co1,2015,224:207-228.
9白玲,谭雪峰,刘平.冠心病患者抗心磷脂抗体与PON、ox-LDL、MDA和SOD的相关性[J].心脏杂志,2014,26(4):453-455. 被引量：3
10Gupta N,Binu KB,Singh S,et al. Low serum PON1 activ-ity:an Independent risk factor for coronary artery disease in North-West Indian type 2 diabetics[J]. Gene, 2012,498 (1):13-19.

二级参考文献40

1迟东升,凌文华,马静,夏敏,侯孟君,王庆,朱惠莲,唐志红,余小平.对氧磷酶_1 55 Met／Leu、对氧磷酶_2 148 Ala／Gly和锰超氧化物歧化酶9 Ala／Val基因多态性与冠心病[J].中华流行病学杂志,2006,27(9):808-813. 被引量：4
2Nicolo D, Monestier M. Antiphospholipid antibodies and atheroscle- rosis[J]. Clinical Immonology, 2004, 112(2) :183 -189.
3Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of beta 2- glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages[ J]. Clin Exp Immu- nol, 1997, 107(3) : 569-573.
4Chung CP, Oeser A, Avalos I, et al. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus[ J]. Lupus, 2006, 15 ( 9 ) :562 - 569.
5de Leeuw K, Freire B, Smit A J, et al. Traditional and non-tradi- tional risk factors contribute to the development of accelerated ather- osclerosis in patients with systemic lupus erythematosus[ J]. Lupus, 2006, 15 (10) :675 - 682.
6Artenjak A, Lakota K, Frank M, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review[ J ]. Autoimmun Rev, 2012, 11 (12) :873 - 882.
7Romero FI, Khamashta M, Hughes GR, et al. Lipoprotein (a) : a new path in atherothrombosis[ J]. Lupus, 2000, 9 ( 3 ) :206 - 209.
8Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biologi- cal activity of minimally oxidized low density lipoprotein[ J]. J Clin Invest, 1995, 96(6) : 2882 -2891.
9Sherer N, Shoenfeld N. Antiphospholipid antibody syndrome, an- tiphospholipid antibodies, and atherosclerosis [ J ]. Curt Atheroscler Rep, 2001, 3(4) :328 -333.
10Liischer TF, Landmesser U, yon Eckardstein A, et al. High-densi- ty lipoprotein : vascular protective effects, dysfunction, and potential as therapeutic target [ J ]. Circulation Research, 2014, 114 ( 1 ) : 171-182.